Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 4/20 | 0.49 |
| ▸ | HTR2C | P28335 | 6/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6497088 | 0.89 | HTR2C (0.51) | HTR2CHTR2BHTR2ARAB9ANR3C1 | |
| SCHEMBL6501012 | 0.89 | PPARG (0.51) | GCGRPPARGRAB9AHPGDNR3C1 | |
| SCHEMBL6489345 | 0.84 | GCGR (0.51) | GCGRRAB9AHPGDNR3C1KDM4E | |
| SCHEMBL6501757 | 0.83 | GCGR (0.54) | GCGRRAB9AHPGDNR3C1KDM4E | |
| SCHEMBL6489905 | 0.83 | PPARG (0.46) | GCGRPPARGRAB9AHPGDKDM4E | |
| SCHEMBL6499999 | 0.81 | PPARG (0.49) | PPARGRAB9ANR3C1KDM4EGAA | |
| SCHEMBL6490174 | 0.81 | GCGR (0.54) | GCGRRAB9AHPGDNR3C1KDM4E | |
| SCHEMBL6501443 | 0.81 | PIK3CA (0.40) | GCGRHTR2CSMN1; SMN2 | |
| SCHEMBL6645978 | 0.80 | HTR2C (0.48) | HTR2CHTR2BHTR2APPARGNR3C1 | |
| SCHEMBL6490549 | 0.80 | ITGB3 (0.41) | GCGRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | GCGR 1784/4885HTR2C 1453/4885HTR2B 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.